352 related articles for article (PubMed ID: 17655371)
21. Clinical pharmacokinetics of allopurinol.
Murrell GA; Rapeport WG
Clin Pharmacokinet; 1986; 11(5):343-53. PubMed ID: 3536254
[TBL] [Abstract][Full Text] [Related]
22. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry.
Lartigue-Mattei C; Chabard JL; Ristori JM; Bussiere JL; Bargnoux H; Petit J; Berger JA
Fundam Clin Pharmacol; 1991; 5(7):621-33. PubMed ID: 1778540
[TBL] [Abstract][Full Text] [Related]
24. Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry.
Liu X; Ni XJ; Shang DW; Zhang M; Hu JQ; Qiu C; Luo FT; Wen YG
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 941():10-6. PubMed ID: 24184830
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Breithaupt B; Tittel M
Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
[TBL] [Abstract][Full Text] [Related]
27. Plasma oxipurinol concentrations during allopurinol therapy.
Emmerson BT; Gordon RB; Cross M; Thomson DB
Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
Wen YF; Brundage RC; Roman YM; Culhane-Pera KA; Straka RJ
Br J Clin Pharmacol; 2023 Oct; 89(10):2964-2976. PubMed ID: 37202871
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects.
Graham S; Day RO; Wong H; McLachlan AJ; Bergendal L; Miners JO; Birkett DJ
Br J Clin Pharmacol; 1996 Apr; 41(4):299-304. PubMed ID: 8730975
[TBL] [Abstract][Full Text] [Related]
30. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
[TBL] [Abstract][Full Text] [Related]
31. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Stamp L; Gow P; Sharples K; Raill B
Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
[TBL] [Abstract][Full Text] [Related]
32. Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M
Am J Vet Res; 1997 May; 58(5):511-5. PubMed ID: 9140560
[TBL] [Abstract][Full Text] [Related]
33. [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
Saji M
Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):640-50. PubMed ID: 9014485
[TBL] [Abstract][Full Text] [Related]
34. [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
Rüffer C; Zorn G; Henkel E; Mitzkat HJ
Arzneimittelforschung; 1982; 32(9):1149-52. PubMed ID: 6890841
[TBL] [Abstract][Full Text] [Related]
35. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
Dalbeth N; Stamp L
Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
[TBL] [Abstract][Full Text] [Related]
36. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.
Appelbaum SJ; Mayersohn M; Dorr RT; Perrier D
Cancer Chemother Pharmacol; 1982; 8(1):93-8. PubMed ID: 7094203
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a thiazide-allopurinol drug interaction.
Hande KR
Am J Med Sci; 1986 Oct; 292(4):213-6. PubMed ID: 3752167
[TBL] [Abstract][Full Text] [Related]
38. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.
Peterson GM; Boyle RR; Francis HW; Oliver NW; Paterson J; von Witt RJ; Taylor GR
Eur J Clin Pharmacol; 1990; 39(4):419-21. PubMed ID: 2076730
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Chu WY; Annink KV; Nijstad AL; Maiwald CA; Schroth M; Bakkali LE; van Bel F; Benders MJNL; van Weissenbruch MM; Hagen A; Franz AR; Dorlo TPC; Allegaert K; Huitema ADR;
Clin Pharmacokinet; 2022 Feb; 61(2):321-333. PubMed ID: 34617261
[TBL] [Abstract][Full Text] [Related]
40. The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Hishe HZ; Stocker SL; Stamp LK; Dalbeth N; Merriman TR; Phipps-Green A; Wright DFB
Clin Transl Sci; 2023 Mar; 16(3):422-428. PubMed ID: 36398357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
